• Skip to main content
  • Skip to footer

Oklahoma Medical Research Foundation | OMRF

  • About
    • General Information
    • Disease Research
    • Training & Outreach
    • Events
    • Careers
    • Contact Us
  • Science
    • Scientist Directory
    • Research Programs
    • Research Centers
    • Core Facilities
    • Scientific Publications
    • Scientific Seminars
    • Technology Ventures
  • News
    • Media Resources
    • News Releases
    • Publications
    • On Your Health
    • Bodywork
  • Patients
    • Anti Aging Study
    • Lupus (SLE)
    • MBTPS1 Related Disorders
    • Multiple Sclerosis
    • Rheumatoid Arthritis
    • Sarcoidosis
    • Sjögren’s Disease
    • Osteoarthritis
    • Other Autoimmune Disorders
  • Donate
    • Donate Now
    • Ways to Give
    • Tax Credit
    • Planned Giving
    • Contact Philanthropy
Home - OMRF News - Archives for drug

drug

OMRF discovers potential therapy for age-related muscle loss

December 4, 2018

An OMRF discovery could potentially open the door for the first drug option to treat age-related muscle weakness and atrophy.

Filed Under: News Tagged With: age, aging, atrophy, cnd1163, diet, drug, exercise, experimental, healthy, Holly, Holly Van Remmen, insulin resistance, loss, muscle, newsok, OKC, oklahama city, Oklahoma Medical Research Foundation, OMRF, option, parkinsons, redox biology, rizwan qaisar, sarcopenia, scientist-news, therapeutic, treatment, van remmen

50 years after terminal diagnosis, Greg Kindell is still here

November 8, 2018

In 1968, doctors told Greg Kindell that he had acute myeloid leukemia and he had just six weeks to live. Now he’s been cancer-free for 50 years.

Filed Under: News Tagged With: 50 years, aml, cancer, cancer free, childhood cancer, diagnosis, drug, experimental, greg kindell, leukemia, live, newsok, OKC, Oklahoma Medical Research Foundation, OMRF, owasso, pryor, remission, survive, terminal, treatment, Tulsa, tulsa world

Oblato acquires all rights to glioblastoma drug from OMRF

October 29, 2018

Oblato, Inc., has acquired all rights from OMRF to OKN-007, an investigational drug for the treatment of a deadly form of brain cancer.

Filed Under: News, Technology Ventures News Tagged With: 007, americans, brain, cancer, clinical, deadly, diagnosis, drug, edward kennedy, Gtree, james battiste, john mccain, Manu Nair, mike schuster, model, news, Norman, Oblato, Oklahoma Medical Research Foundation, okn, OKN-007, OMRF, Rheal, rheal towner, robert floyd, scientist-news, Stephenson Cancer Center, technology, testing, therapy, Towner, treatment, trial, tumor, university of oklahoma

New OMRF grant will focus on autoimmune condition

October 24, 2018

The project will focus on comparing certain immune cells in patients with Sjögren’s to those of healthy controls.

Filed Under: News Tagged With: A., autoimmune disease, cells, condition, controls, darise farris, drug, Farris, grant, immune, Kathy, memory, national institute of arthritis and musculoskeletal and skin diseases, National Institutes of Health, newsok, NIH, OKC, Oklahoma City, Oklahoma Medical Research Foundation, OMRF, scientist-news, sivils, Sjogren's, studies, syndrome, targets, therapeautic, therapy

Staying alive: Can an experimental OMRF drug stop Mike Schuster’s brain cancer?

September 11, 2018

As Mike Schuster nears the three-year anniversary of his diagnosis with glioblastoma, he’s already doubled the life expectancy for patients with the deadly cancer.

Filed Under: News, Technology Ventures News Tagged With: aggressive, battiste, brain, brain cancer, cancer, deadly, death, develop, disease, drug, glioblastoma, john mccain, life expectancy, live, longer, mike schuster, MRI, newsok, Norman, OKC, Oklahoma City, Oklahoma Medical Research Foundation, OKN-007, OMRF, OUHSC, patients, Rheal, scientist-news, Stephenson Cancer Center, Towner, tumor

New hope in the fight against sickle cell disease

June 14, 2018

For Mary Long, the answer to her pain may, literally, be right around the corner.

Filed Under: News Tagged With: biology, biotechnology, blood, cell, disease, drug, mary long, McEver, news, newsok, novartis, OKC, Oklahoma Medical Research Foundation, OMRF, option, P-selectin, pain, patients, rodger, Rodger McEver, scd, scientist-news, selexys, sickle cell, therapy

  • « Go to Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Go to Next Page »

Before Footer

Equal Opportunity Employer

Footer

  • Jobs
  • Directory
  • Donor Privacy Statement
  • Ethics Point
  • Intranet
Facebook Twitter Instagram Linkedin

Subscribe to OMRF News
  • Contact
  • Careers
  • Donor Privacy
  • Ethics Point
  • Intranet
OMRF Logo
OKLAHOMA MEDICAL RESEARCH FOUNDATION
825 NE 13th St.
Oklahoma City, OK 73104
(405) 271-6673
Charity navigatorUnited WayTop Workplace